Clinical Trial Update: Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating carfilzomib with dexamethasone in Chinese patients with relapsed and refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Amgen | Conditions: Relapsed and Refractory Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2019-11-21